Evidence map›Paper›PMID 30136421›Full record

ArticleHepatology (Baltimore, Md.)2019

Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma.

Ryan A Hlady, Aishwarya Sathyanarayan, Joyce J Thompson, Dan Zhou, Qunfeng Wu, Kien Pham, Jeong-Heon Lee, Chen Liu, Keith D Robertson

Open access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Crosstalk BetweenCancers · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Clinical significance of RNA methylation in hepatocellular carcinoma.Cell communication and signaling : CCS · 2024
    Review
  19. Blood biomarkers of hepatocellular carcinoma: a critical review.Frontiers in cell and developmental biology · 2024
    Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ryan A HladyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.ORCID 0000-0002-2829-4237
Aishwarya SathyanarayanDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Joyce J ThompsonDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Dan ZhouDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Qunfeng WuDepartment of Pathology and Laboratory Medicine, New Jersey Medical School, The State University of New Jersey, Rutgers, Newark, NJ.
Kien PhamDepartment of Pathology and Laboratory Medicine, New Jersey Medical School, The State University of New Jersey, Rutgers, Newark, NJ.
Jeong-Heon LeeDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4007-9166
Chen LiuDepartment of Pathology and Laboratory Medicine, New Jersey Medical School, The State University of New Jersey, Rutgers, Newark, NJ.
Keith D RobertsonDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Mayo Clinic · USRutgers, The State University of New Jersey · USMayo Clinic in Arizona · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Epigenetic Heterogeneity as a Driver of Liver Disease and CancerR01AA027179 · NIAAA · MAYO CLINIC ROCHESTER · PI LIU, CHEN, ROBERTSON, KEITH D · 2018 to 2022
$2.5M
Epigenetic Mechanisms Underlying Hepatitis C-Induced HepatocarcinogenesisR01DK110024 · NIDDK · MAYO CLINIC ROCHESTER · PI LIU, CHEN, ROBERTSON, KEITH D · 2017 to 2020
$2.4M
NIAAA NIH HHS R01 AA027179NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK110024
6 · The paper itself

Abstract

Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post-translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments. The epigenome of HCC remains understudied. To better understand the epigenetic underpinnings of HCC, we performed a genome-wide assessment of 5mC, 5hmC, four histone modifications linked to promoter/enhancer function (H3K4me1, H3K27ac, H3K4me3, and H3K27me3), and transcription across normal, cirrhotic, and HCC liver tissue. Implementation of bioinformatic strategies integrated these epigenetic marks with each other and with transcription to provide a comprehensive epigenetic profile of how and when the liver epigenome is perturbed during progression to HCC. Our data demonstrate significant deregulation of epigenetic regulators combined with disruptions in the epigenome hallmarked by profound loss of 5hmC, locus-specific gains in 5mC and 5hmC, and markedly altered histone modification profiles, particularly remodeling of enhancers. Data integration demonstrates that these marks collaborate to influence transcription (e.g., hyper-5hmC in HCC-gained active enhancers is linked to elevated expression) of genes regulating HCC proliferation. Two such putative epigenetic driver loci identified through our integrative approach, COMT and FMO3, increase apoptosis and decrease cell viability in liver-derived cancer cell lines when ectopically re-expressed. Conclusion: Altogether, integration of multiple epigenetic parameters is a powerful tool for identifying epigenetically regulated drivers of HCC and elucidating how epigenome deregulation contributes to liver disease and HCC.

Indexed as

EpigenomeCarcinoma, HepatocellularCase-Control StudiesDNA MethylationHistone CodeHumansLiverLiver CirrhosisLiver Neoplasms

Identifiers

PMID30136421
PMCPMC6351162
OpenAlexW2888499439

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.